CytoSorbents reported strong Q4 results, says D. Boral Capital
D. Boral Capital says CytoSorbents (CTSO) reported a strong Q4, with product revenue growth estimated between 22% and 25% year-over-year. The ...
Lineage Cell price target lowered to $2 from $3 at D. Boral Capital
D. Boral Capital lowered the firm’s price target on Lineage Cell Therapeutics (LCTX) to $2 from $3 and keeps a Buy rating on the shares. The ...
D. Boral Capital Reaffirms “Buy” Rating for Quince Therapeutics (NASDAQ:QNCX)
D. Boral Capital reissued their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX – Free Report) in a research report released on Thursday morning,Benzinga reports. D. Boral Capital currently ...
D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and ...
Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital
D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius ...
Hosted on MSN4d
D. Boral Capital Upgrades Citius Pharmaceuticals (CTXR)
Fintel reports that on December 30, 2024, D. Boral Capital upgraded their outlook for Citius Pharmaceuticals (NasdaqCM:CTXR) from Hold to Buy. Analyst Price Forecast Suggests 121.74% Upside As of ...
NRx Pharmaceuticals (NASDAQ:NRXP) Receives Buy Rating from D. Boral Capital
D. Boral Capital reiterated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP – Free Report) in a research note released on Tuesday morning,Benzinga reports. D. Boral Capital currently ...
Hosted on MSN11d
D. Boral Capital Initiates Coverage of Omeros (OMER) with Buy Recommendation
Fintel reports that on December 23, 2024, D. Boral Capital initiated coverage of Omeros (NasdaqGM:OMER) with a Buy ...
Morningstar16d
D. Boral Capital Acted as Exclusive Placement Agent to Webuy Global Ltd (Nasdaq: WBUY) in connection with its $3.7 Million Registered Direct Offering
D. Boral Capital LLC acted as the exclusive placement agent for the offering. Ortoli Rosenstadt LLP acted as counsel to the Company and Hunter Taubman Fischer & Li LLC acted as counsel to D.
Merced Sun-Star23d
FAVO Capital, Inc Closes $2 Million Bridge Raise Led by D. Boral Capital
D. Boral Capital is acting as the exclusive placement agent for the offering. The securities were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended ...
Citius股票评级上调至买入，Boral Capital设定目标价
周一，Boral Capital将Citius Pharmaceuticals (NASDAQ: CTXR)的股票评级从持有上调至买入，并设定9.00美元的目标价。此次上调反映了Boral Capital估值模型的调整，现在考虑了拆股和公司Mino-Lok产品预期批准时间表的修订。根据InvestingPro数据，该股在过去一周表现出强劲势头，上涨26.46%，但仍远低于52周高点26.75美元。
D. Boral Capital开始对Avita Medical股票进行覆盖，引用美国市场渗透率
D. Boral Capital的分析师强调了Recell有潜力为一系列产品铺平道路，如PermeaDerm和Cohealyx，这些产品旨在管理全方位的软组织和深层组织护理。这一潜力得到了公司在过去十二个月中32.24%的收入增长和85.66%的强劲毛利率的支持。Avita Medical在美国的市场渗透是该公司模型的主要焦点，并预期会进一步扩大市场。